Ironwood Pharmaceuticals, Inc.

Forest Laboratories Holdings Limited

Microbia, Inc.

Ironwood Pharmaceutical, Inc.

Ironwwod Pharmaceuticals, Inc.

Angelika Fretzen

Mark G Currie

Daniel P Zimmer

Marco Kessler

Brian Cali

Joel D Moore

Rajesh R Iyengar

Mahendra G Dedhiya

G Todd Milne

Yun Mo

Hong Zhao

Thea Norman

Takashi Nakai

Ara Mermerian

Nicholas Robert Perl

Shalina Mahajan-Miklos

Charles Kim

Li Jing Sun

Timothy Claude Barden

Thomas Wai-Ho Lee

G-Yoon Jamie Im

Steven Richard Witowski

Jason Matthew Rohde

Alfredo Grossi

Paul A Renhowe

Xiang Y Yu

Kevin Sprott

Colleen Hudson

Ahmad Hashash

Anil Chhettry

Jane Yang

James Jia

Andreas Grill

Ritesh Sanghvi

Caroline Kurtz

Robert Solinga

Bo Peng

Vladimir Volchenok

Mohammad Mafruhul Bari

Harvey Schneier

Bernard Joseph Lavins

Matthew Miller

Mahendra Dedihiya

Paul Allan Renhowe

Jeffrey Johnston

Brian M Cali

The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.

Stable formulations of linaclotide

Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed. 

SGC stimulators

The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.

Treatments for gastrointestinal disorders

The present disclosure relates to compounds useful as inhibitors of the enzyme Fatty Acid Amide Hydrolase (FAAH). The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment or prevention of various disorders. Compounds of the invention are described in Table 1.

FAAH inhibitors

The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including irritable bowel syndrome and constipation.

The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including inflammatory bowel disease (IBD), diverticulitis, colon cancer, an inflammatory disorder, obesity, congestive heart failure, benign prostatic hyperplasia (BPH), pain, salt retention or fluid retention.

Compound of Table I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.

2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators

The present invention provides peptides that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms.

Treatments of gastrointestinal disorders

Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr ('linaclotide'; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.

Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration

Peptides that act as GC-C receptor agonists and contain at least one D-cys and are useful for the treatment of diuresis and heart disease as well as other disorders are described.

Methods and compositions for the treatment of heart failure and other disorders

The present invention relates to stable compositions comprising linaclotide, as well as to various methods and processes for the preparation and use of the compositions.

Formulations comprising linaclotide

Growing community of inventors

Somerville, MA, United States of America

Angelika Fretzen